Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

TY - JOUR

T1 - Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

AU - Nielsen, Lene Ryom

AU - Mocroft, Amanda

AU - Kirk, Ole

AU - Ross, Michael

AU - Reiss, Peter

AU - Fux, Christophe A

AU - Morlat, Philippe

AU - Moranne, Olivier

AU - Smith, Colette

AU - El-Sadr, Wafaa

AU - Law, Matthew

AU - Lundgren, Jens D

PY - 2014/1/14

Y1 - 2014/1/14

N2 - Objectives: Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown. Design: D:A:D participants with at least three estimated glomerular filtration rates (eGFR) after February 2004 were followed until the first of advanced CKD (confirmed eGFR≤30 ml/min,≥3 months apart), ESRD (dialysis ≥3 months/transplantation), 6 months after last visit or February 2012. Methods: Poisson regression was used to assess risk factors for advanced CKD/ESRD including exposure to potential nephrotoxic antiretroviral drugs and antiretroviral drug discontinuation rates according to latest eGFR. Results: Among 35 192 persons contributing 200 119 person years of follow-up (PYFU), 135 (0.4%) developed advanced CKD (n=114)/ESRD (n=21); incidence rate=0.67 [95% confidence interval (CI), 0.56-0.79]/1000 PYFU. Tenofovir (TDF) was particularly frequently discontinued as eGFR declined. After adjustment, those previously exposed but currently off TDF had similar advanced CKD/ESRD rate ratios compared with those unexposed [1.00 (95% CI, 0.66-1.51)], while those currently on TDF had reduced rates [0.23 (95% CI, 0.13-0.41)]. No consistent associations with other antiretroviral drugs were seen. Results were robust after time-lagging antiretroviral drug exposure, stratifying by baseline eGFR, and allowing for competing risks. Other predictors were diabetes, hypertension, baseline eGFR, smoking and current CD4 + cell count. The incidence rate in nonsmokers with baseline eGFR60 and no diabetes or hypertension was 0.16 (95% CI 0.09-0.26)/1000 PYFU. Conclusion: Neither current nor recent antiretroviral drug use predicted advanced CKD/ESRD during 6 years median follow-up in a large, heterogenenous and primarily white cohort. TDF discontinuation rates increased with decreasing eGFR, leaving a selected group still on TDF at lower advanced CKD/ESRD risk. Traditional renal risk factors and current CD4+ cell count were the strongest advanced CKD/ESRD predictors.

AB - Objectives: Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown. Design: D:A:D participants with at least three estimated glomerular filtration rates (eGFR) after February 2004 were followed until the first of advanced CKD (confirmed eGFR≤30 ml/min,≥3 months apart), ESRD (dialysis ≥3 months/transplantation), 6 months after last visit or February 2012. Methods: Poisson regression was used to assess risk factors for advanced CKD/ESRD including exposure to potential nephrotoxic antiretroviral drugs and antiretroviral drug discontinuation rates according to latest eGFR. Results: Among 35 192 persons contributing 200 119 person years of follow-up (PYFU), 135 (0.4%) developed advanced CKD (n=114)/ESRD (n=21); incidence rate=0.67 [95% confidence interval (CI), 0.56-0.79]/1000 PYFU. Tenofovir (TDF) was particularly frequently discontinued as eGFR declined. After adjustment, those previously exposed but currently off TDF had similar advanced CKD/ESRD rate ratios compared with those unexposed [1.00 (95% CI, 0.66-1.51)], while those currently on TDF had reduced rates [0.23 (95% CI, 0.13-0.41)]. No consistent associations with other antiretroviral drugs were seen. Results were robust after time-lagging antiretroviral drug exposure, stratifying by baseline eGFR, and allowing for competing risks. Other predictors were diabetes, hypertension, baseline eGFR, smoking and current CD4 + cell count. The incidence rate in nonsmokers with baseline eGFR60 and no diabetes or hypertension was 0.16 (95% CI 0.09-0.26)/1000 PYFU. Conclusion: Neither current nor recent antiretroviral drug use predicted advanced CKD/ESRD during 6 years median follow-up in a large, heterogenenous and primarily white cohort. TDF discontinuation rates increased with decreasing eGFR, leaving a selected group still on TDF at lower advanced CKD/ESRD risk. Traditional renal risk factors and current CD4+ cell count were the strongest advanced CKD/ESRD predictors.

U2 - 10.1097/qad.0000000000000042

DO - 10.1097/qad.0000000000000042

M3 - Journal article

C2 - 24361680

SN - 1350-2840

VL - 28

SP - 187

EP - 199

JO - AIDS, Supplement

JF - AIDS, Supplement

IS - 2

ER -